Statins, stroke outcome, and stroke prevention: When should we start treatment?

Stroke

Volumn 35, Issue 5, 2004, Pages 1121-1123

  Streifler, Jonathan Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROPROTECTIVE AGENT;

CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERTENSION; LONG TERM CARE; NOTE; PRIORITY JOURNAL; REDUCTION; RISK FACTOR; STROKE; THROMBOEMBOLISM; VASODILATATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION; HOSPITALIZATION; METHODOLOGY; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2342663728     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000126481.79085.47     Document Type: Note

References (18)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1429.
2. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT- LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149-1158.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361: 2005-2016.
4. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I for the NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90:1320-1325.
5. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
6. Sillesen H. Statin for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis. 2004; 18:1-2.
7. The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovasc Dis. 2003;16:389-395.
8. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
9. Vaughan CJ. Prevention of stroke and dementia with statin: effects beyond lipid lowering. Am J Cardiol 2003;91:23B-29B.
10. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern t. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
11. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
12. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53: 743-751.
13. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
14. Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke. 2001;32: 1112-1115.
15. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Escudero D, Hereu P, Molina C, Quintana M, Alvarez-Sabin J. Safety and efficacy of statin in the acute phase of ischemic stroke: the MISTICS Trial. Stroke. 2004;35:293. Abstract.
16. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonadarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia MD, Molina-Porcel L, Diaz-Manera J, Marti-Vilalta JL. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35:1117-1123.
17. Selim M, Savitz S, Gomes J, Caplan L, Linfante I, Leary M, Finely A, Schlaug G. Effects of prior use of angiotensin-converting enzyme inhibitors on stroke severity. Stroke. 2004;35:235. Abstract.
18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.